Trial reportBMC cancer2012
Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases.
Trial report in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2020Pooled it
- Does adjuvant chemotherapy improve the prognosis of patients after resection of pulmonary metastasis from colorectal cancer? A systematic review and meta-analysis.International journal of colorectal disease · 2019Pooled it
- Development and validation of a prognostic scoring system for patients with colorectal cancer hepato-pulmonary metastasis: a retrospective study.BMC cancer · 2022Trial
- Neoadjuvant therapy for resectable colorectal cancer pulmonary oligometastases: a retrospective cohort study.International journal of colorectal disease · 2025Article
- A Retrospective Analysis of Real-Life Management of Colorectal Cancer Lung-Limited Metastases Treated with Surgery: Outcomes and Prognostic Factors.Journal of clinical medicine · 2024Article
- Depletion of CPNE7 sensitizes colorectal cancer to 5-fluorouracil by downregulating ATG9B expression.Journal of cellular and molecular medicine · 2024Article
- Prognosis of patients with recurrence after pulmonary metastasectomy for colorectal cancer.General thoracic and cardiovascular surgery · 2020Article
- Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases.European radiology · 2019Observational
- Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition).Journal of hematology & oncology · 2019Review
- Adjuvant chemotherapy improves prognosis of resectable stage IV colorectal cancer: a comparative study using inverse probability of treatment weighting.Therapeutic advances in medical oncology · 2019Article
- miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer.Cell death & disease · 2017Article
- Management of resectable colorectal lung metastases.Clinical & experimental metastasis · 2016Review
- Reply: Comment on 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colo-rectal cancer'.British journal of cancer · 2015Article
- Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?World journal of gastroenterology · 2014Review
- Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer.Thoracic cancer · 2014Article
- The management of the advanced colorectal cancer: management of the pulmonary metastases.Journal of thoracic disease · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgery is often advocated in patients with resectable pulmonary metastases from colorectal cancer (CRC). Our study aims to evaluate peri-operative chemotherapy in patients with metastastic CRC undergoing pulmonary metastasectomy.
methodsPatients treated for CRC who underwent pulmonary metastasectomy by a single surgeon were identified. Outcome measures included survival, peri-operative complications, radiological and histological evidence of chemotherapy-induced lung toxicities.
resultsBetween 1997 and 2009, 51 eligible patients were identified undergoing a total of 72 pulmonary resections. Thirty-eight patients received peri-operative chemotherapy, of whom 9 received an additional biological agent. Five-year overall survival rate was 72% in the whole cohort - 74% and 68% in those who received peri-operative chemotherapy (CS) and those who underwent surgery alone (S) respectively. Five-year relapse free survival rate was 31% in the whole cohort - 38% and ≤18% in CS and S groups respectively. Only 8% had disease progression during neoadjuvant chemotherapy. There were no post-operative deaths. Surgical complications occurred in only 4% of patients who received pre-operative chemotherapy. There was neither radiological nor histological evidence of lung toxicity in resected surgical specimens.
conclusionsPeri-operative chemotherapy can be safely delivered to CRC patients undergoing pulmonary metastasectomy. Survival in this selected group of patients was favourable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.